Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
作者信息
Park Sang Hyoung, Ye Byong Duk, Yang Suk-Kyun
机构信息
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
出版信息
Gut Liver. 2022 Jan 15;16(1):138-140. doi: 10.5009/gnl210246.
Abstract
摘要
相似文献
1
Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?英夫利昔单抗与阿达木单抗：我们能为溃疡性结肠炎患者选对正确的药物吗？
Gut Liver. 2022 Jan 15;16(1):138-140. doi: 10.5009/gnl210246.
2
Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.抗肿瘤坏死因子α在溃疡性结肠炎门诊治疗中的实际疗效
World J Gastroenterol. 2015 Mar 21;21(11):3282-90. doi: 10.3748/wjg.v21.i11.3282.
3
Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.真实世界实践中，一线和二线肿瘤坏死因子抑制剂治疗难治性溃疡性结肠炎患者的疗效。
Indian J Gastroenterol. 2020 Dec;39(6):565-575. doi: 10.1007/s12664-020-01092-1. Epub 2020 Oct 27.
4
Submandibular Sialoadenitis in an Infant Exposed to Adalimumab and Infliximab in Utero.子宫内暴露于阿达木单抗和英夫利昔单抗的婴儿发生下颌下涎腺炎
J Crohns Colitis. 2017 Oct 1;11(10):1284-1285. doi: 10.1093/ecco-jcc/jjx045.
5
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.在首支皮下抗 TNF 药物治疗失败后，比较维得利珠单抗和英夫利昔单抗治疗溃疡性结肠炎的疗效和安全性：一项多中心队列研究。
Aliment Pharmacol Ther. 2020 May;51(9):852-860. doi: 10.1111/apt.15680. Epub 2020 Mar 22.
6
Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease.英夫利昔单抗或阿达木单抗的既往抗体与炎症性肠病患者对维多珠单抗的免疫原性相关。
Clin Gastroenterol Hepatol. 2023 Oct;21(11):2978-2980.e2. doi: 10.1016/j.cgh.2022.10.037. Epub 2022 Nov 11.
7
An update on anti-TNF agents in ulcerative colitis.溃疡性结肠炎中抗TNF药物的最新进展。
Gastroenterol Clin North Am. 2014 Sep;43(3):479-94. doi: 10.1016/j.gtc.2014.05.006.
8
Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy.阿达木单抗和英夫利昔单抗治疗初治的抗肿瘤坏死因子治疗的溃疡性结肠炎的疗效和患者偏好的前瞻性比较。
Medicine (Baltimore). 2017 Aug;96(32):e7800. doi: 10.1097/MD.0000000000007800.
9
Small-Fiber Neuropathy in a Pediatric Patient Following Anti-Tumor Necrosis Factor-α Therapy for Ulcerative Colitis.一名溃疡性结肠炎患儿接受抗肿瘤坏死因子-α治疗后出现的小纤维神经病变
J Pediatr Gastroenterol Nutr. 2018 Jun;66(6):e159-e161. doi: 10.1097/MPG.0000000000001992.
10
[Golimumab Therapy in Ulcerative Colitis].[戈利木单抗治疗溃疡性结肠炎]
Korean J Gastroenterol. 2016 Feb;67(2):64-73. doi: 10.4166/kjg.2016.67.2.64.
本文引用的文献
1
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study.阿达木单抗在日本克罗恩病患者中的长期安全性和有效性：一项真实世界研究的3年结果
Intest Res. 2021 Oct;19(4):408-418. doi: 10.5217/ir.2020.00025. Epub 2020 Nov 20.
2
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study.阿达木单抗治疗溃疡性结肠炎的安全性和有效性：一项大规模、前瞻性、多中心观察性研究的结果
Intest Res. 2021 Oct;19(4):419-429. doi: 10.5217/ir.2020.00033. Epub 2020 Nov 10.
3
Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018.2000年至2018年期间，在溃疡性结肠炎发病率较低的国家中，溃疡性结肠炎自然史的时间趋势。
Intest Res. 2021 Apr;19(2):186-193. doi: 10.5217/ir.2020.00028. Epub 2020 Aug 18.
4
Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis.比较英夫利昔单抗与阿达木单抗治疗生物初治溃疡性结肠炎患者的长期结局。
Gut Liver. 2021 Mar 15;15(2):232-242. doi: 10.5009/gnl19433.
5
Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns?日本的炎症性肠病——与西方的情况相似还是不同？
J Anus Rectum Colon. 2020 Jan 30;4(1):1-13. doi: 10.23922/jarc.2019-003. eCollection 2020.
6
Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.韩国首尔松坡-江东地区基于人群队列的溃疡性结肠炎长期预后及其在1986年至2015年间的时间变化
Gut. 2020 Aug;69(8):1432-1440. doi: 10.1136/gutjnl-2019-319699. Epub 2019 Dec 10.
7
Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study.阿达木单抗治疗韩国溃疡性结肠炎患者的长期结局：一项基于医院的队列研究。
Gut Liver. 2020 May 15;14(3):347-356. doi: 10.5009/gnl19137.
8
A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015.1986-2015 年韩国首尔松坡-姜洞地区炎症性肠病的 30 年流行病学趋势分析。
J Crohns Colitis. 2019 Oct 28;13(11):1410-1417. doi: 10.1093/ecco-jcc/jjz081.
9
A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study.炎症性肠病创新研究的新机遇：韩国中重度溃疡性结肠炎（MOSAIK）队列研究
Intest Res. 2019 Jan;17(1):1-5. doi: 10.5217/ir.2019.00005. Epub 2019 Jan 25.
10
Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study.2001年至2015年台湾炎症性肠病的流行病学趋势：一项基于全国人口的研究。
Intest Res. 2019 Jan;17(1):54-62. doi: 10.5217/ir.2018.00096. Epub 2018 Nov 20.
Zotero 插件